BIOLASE, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-17: Form 8-K; Period of report 2011-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2011-11-15: Form 8-K; Period of report 2011-11-11; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2011-11-07: Form 8-K; Period of report 2011-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-09-27: Form 8-K; Period of report 2011-09-27; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-17 | 8-K | 2011-11-16 | 7.01 Regulation FD Disclosure | 7.01 On November 16, 2011, Frederick D. Furry, Chief Financial Officer and Chief Operating Officer of Biolase Technology, Inc. (the “Company”), will deliver a presentation at the Lazard Capital Markets 8th Annual Healthcare Conference that will include a written communication comprised of slides. | d257409d8k.htm |
| 2011-11-15 | 8-K | 2011-11-11 | 7.01 Regulation FD Disclosure | 7.01 On November 11, 2011, the Board of Directors of Biolase Technology, Inc. (the "Company") declared a one percent stock dividend. | htm_43514.htm |
| 2011-11-07 | 8-K | 2011-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2011. | htm_43415.htm |
| 2011-09-27 | 8-K | 2011-09-27 | 7.01 Regulation FD Disclosure | 7.01 On September 27, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”) will deliver a presentation at the Sixth Annual JMP Securities Healthcare Conference that will include a written communication comprised of slides. | d237137d8k.htm |
| 2011-09-21 | 8-K | 2011-09-21 | 7.01 Regulation FD Disclosure | 7.01 On September 21, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”) will deliver a presentation at the UBS Global Life Sciences Conference that will include a written communication comprised of slides. | d235050d8k.htm |
| 2011-09-12 | 8-K | 2011-09-12 | 7.01 Regulation FD Disclosure | 7.01 On September 12, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”) and Frederick D. Furry, Chief Financial Officer of the Company, will deliver a presentation at the Rodman & Renshaw Annual Global Investment Conference that will include a written communication comprised of slides. | a60108e8vk.htm |
| 2011-08-22 | 8-K | 2011-08-18 | 7.01 Regulation FD Disclosure | 7.01 On August 18, 2011, the Board of Directors of the Biolase Technology, Inc. (the "Company") declared a one percent stock dividend. | htm_42749.htm |
| 2011-08-10 | 8-K | 2011-08-10 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 10, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2011. 8.01 On August 10, 2011, the Company issued a press release announcing approval by its Board of Directors of the repurchase of up to 2,000,000 shares of the Company’s outstanding common stock. | htm_42651.htm |
| 2011-07-14 | 8-K | 2011-07-13 | 2.02 Results of Operations and Financial Condition | 2.02 On July 13, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing preliminary financial results for the second quarter ended June 30, 2011. | htm_42299.htm |
| 2011-07-05 | 8-K | 2011-06-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_42222.htm |
| 2011-06-29 | 8-K | 2011-06-24 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 3.02 On June 24, 2011, Biolase Technology, Inc. (the "Company") entered into a securities purchase agreement with certain institutional investors whereby it agreed to sell an aggregate of 1,625,947 shares of the Company’s common stock (the "Common Stock") at a price of $5.55 per share, together with five-year warrants to purchase 812,973 shares of Common Stock having an exercise price of $6.50 per share (the "Warrants"). 7.01 On June 24, 2011, the Company issued a press release entitled "Biolase to Raise Approximately $9 Million from Institutional Investors in Private Placement." A copy of the press release is furnished herewith as Exhibit 99.1. | htm_42177.htm |
| 2011-06-16 | 8-K | 2011-06-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_42048.htm |
| 2011-06-14 | 8-K | 2011-06-14 | 7.01 Regulation FD Disclosure | 7.01 On June 14, 2011, Biolase Technology, Inc. (the "Company") issued a press release entitled "Biolase Set to Join Russell 200 Index," announcing that the Company was added to the preliminary list of additions to the Russell 2000 Index as part of Russell Investment's 2011 reconstitution process, which list will be final after the close of U.S. markets on June 24, 2011. | htm_42025.htm |
| 2011-06-01 | 8-K | 2011-05-31 | 7.01 Regulation FD Disclosure | 7.01 On May 31, 2011, the Board of Directors of the Biolase Technology, Inc. (the "Company") declared a one percent stock dividend. | htm_41918.htm |
| 2011-05-11 | 8-K | 2011-05-10 | 7.01 Regulation FD Disclosure | 7.01 On May 10, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”), and Frederick D. Furry, Chief Financial Officer of the Company, will deliver a presentation at the 2nd Annual Bright Lights Conference that will include a written communication comprised of slides. | c16998e8vk.htm |
| 2011-05-09 | 8-K | 2011-05-05 | 2.02 Results of Operations and Financial Condition; 5.07 Submission of Matters to a Vote of Security Holders | 2.02 On May 9, 2011, Biolase Technology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2011. 5.07 On May 5, 2011, the 2011 Annual Meeting of Stockholders of the Company was held at the Company's headquarters, 4 Cromwell, Irvine, California. | htm_41646.htm |
| 2011-05-05 | 8-K | 2011-05-05 | 7.01 Regulation FD Disclosure | 7.01 Biolase Technology, Inc. (the “Company”) expects to make a slide presentation at its annual meeting of stockholders, scheduled to be held on May 5, 2011. | c16660e8vk.htm |
| 2011-04-12 | 8-K | 2011-04-07 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On April 8, 2011, the Company issued a press release announcing the offering described in Item 1.01 above. | htm_41319.htm |
| 2011-04-06 | 8-K | 2011-04-06 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On April 6, 2011, Biolase Technology, Inc. (the “Company”) issued a press release announcing preliminary net revenue results for the first quarter ended March 31, 2011. 7.01 On April 6, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of the Company will deliver a presentation at the 10th Annual Needham Healthcare Conference that will include a written communication comprised of slides. | c15233e8vk.htm |
| 2011-03-16 | 8-K | 2011-03-16 | 7.01 Regulation FD Disclosure | 7.01 On March 16, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the “Company”) will deliver a presentation at the Roth 23rd Annual Growth Stock Conference that will include a written communication comprised of slides. | c14265e8vk.htm |
| 2011-03-10 | 8-K | 2011-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2010. | htm_41017.htm |
| 2011-02-23 | 8-K | 2011-02-23 | 2.02 Results of Operations and Financial Condition | 2.02 On February 23, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing unaudited preliminary 2010 fourth quarter net income. | htm_40840.htm |
| 2011-01-24 | 8-K | 2011-01-20 | 2.02 Results of Operations and Financial Condition | 2.02 On January 20, 2011, Biolase Technology, Inc. (the "Company") issued a press release announcing preliminary financial results for the fourth quarter ended December 31, 2010, the declaration by the Company's Board of Directors of a quarterly stock dividend on March 31, 2011 (to shareholders of record on March 15, 2011), the establishment of an annual stock dividend policy, and annual revenue guidance for the 2011 fiscal year. | htm_40465.htm |